Mitani Sangyo (8285) · RiskDropped
Decline in sales due to the discontinuation of certain active pharmaceutical ingredient products
First written in FY2020-Q3. 1 of 2 entries say "Dropped", first in FY2021-Q1. Latest entry: FY2021-Q1.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Sales decline due to the discontinuation of pharmaceutical API productsA theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2021-Q1DroppedAnnual reportThe explanation of active pharmaceutical ingredients for the current quarter does not directly mention the discontinuation of certain products, instead citing changes in customers' production plans for the company's products as a factor behind the revenue decline.
- FY2020-Q3First statedAnnual report
「Although sales of proprietary products increased, API revenue declined because the company discontinued handling certain merchandise.」
The discontinuation of certain products actually occurred and was mentioned for the first time as a factor behind the decline in active pharmaceutical ingredient revenue.